Acorda Therapeutics, Inc. today announced data analyses showing that people with multiple sclerosis (MS) who responded to Ampyra™ (dalfampridine) Extended Release Tablets, 10 mg had comparable improvements in their walking regardless of baseline walking speed or overall level of MS-related disability1.
In addition, Ampyra responders, regardless of baseline disability, showed clinically meaningful improvement on the 12-Item MS Walking Scale (MSWS-12), a patient-based questionnaire that measures the impact of MS on the patient's reported ability to perform daily activities related to walking. These and other post hoc analyses of Ampyra clinical trial and extension study data will be presented at the 63rd American Academy of Neurology (AAN) Annual Meeting being held April 9-16 in Honolulu, Hawaii.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310